Antidepressive Agents, Tricyclic
"Antidepressive Agents, Tricyclic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system.
| Descriptor ID |
D000929
|
| MeSH Number(s) |
D27.505.954.427.700.122.055
|
| Concept/Terms |
Antidepressive Agents, Tricyclic- Antidepressive Agents, Tricyclic
- Tricyclic Antidepressive Agents
- Agents, Tricyclic Antidepressive
- Antidepressant Drugs, Tricyclic
- Drugs, Tricyclic Antidepressant
- Tricyclic Antidepressant Drugs
- Antidepressants, Tricyclic
- Tricyclic Antidepressants
|
Below are MeSH descriptors whose meaning is more general than "Antidepressive Agents, Tricyclic".
Below are MeSH descriptors whose meaning is more specific than "Antidepressive Agents, Tricyclic".
This graph shows the total number of publications written about "Antidepressive Agents, Tricyclic" by people in this website by year, and whether "Antidepressive Agents, Tricyclic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 3 | 0 | 3 |
| 2004 | 1 | 1 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antidepressive Agents, Tricyclic" by people in Profiles.
-
Pharmacologically distinct pramipexole-mediated akinesia vs. risk-taking in a rat model of Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2016 10 03; 70:77-84.
-
Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedside. Pharmacol Ther. 2012 Dec; 136(3):343-53.
-
Mirtazapine alters cue-associated methamphetamine seeking in rats. Biol Psychiatry. 2011 Feb 01; 69(3):275-81.
-
SNRIs in the management of acute major depressive disorder. J Clin Psychiatry. 2004; 65 Suppl 17:11-8.
-
WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr. 2003 Aug; 8(8 Suppl 1):53-61.
-
WCA recommendations for the long-term treatment of panic disorder. CNS Spectr. 2003 Aug; 8(8 Suppl 1):17-30.
-
Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry. 2000 Jan; 57(1):76-82.
-
The pharmacotherapy of panic disorder. Bull Menninger Clin. 1996; 60(2 Suppl A):A54-75.
-
Quantitative serum toxic screening in the management of suspected drug overdose. Am J Emerg Med. 1990 Jan; 8(1):16-22.
-
Vasopressor challenges during chronic MAOI or TCA treatment in anesthetized dogs. Life Sci. 1987 Jun 29; 40(26):2587-95.